Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial

This research is being done to test a combination of two drugs, Izalontamab Brengitecan (iza-bren) and Adagrasib, in patients with advanced KRAS G12C-mutant NSCLC that hasn't responded to other treatments. The purpose is to see if this combination works better than existing treatments for people whose cancer keeps growing despite KRAS G12C inhibitors.

Inclusion Criteria: * Patients must have histologically or cytologically confirmed diagnosis of NSCLC or NSCLC predominant histology. * Patients must have a diagnosis of metastatic or locally advanced NSCLC not amenable to curative therapy * Tumor must harbor a KRAS G12C mutation. Testing available through multigene NGS panels performed in the Molecular Diagnostics Laboratory in UT MD Anderson Cancer Center and can be performed using either tissue or blood assays. Use of standard of care (SOC) results are allowed to meet this requirement. * Patients must have progressed on a prior KRAS G12C inhibitor as monotherapy or as combination therapy. * Patients must have received at least one prior line of therapy and up to 3 prior lines of therapy. * Patients must have measurable disease per RECIST v1.1. * Age ≥18 years - no dosing or adverse event data are currently available on the use of izabren and adagrasib in patients \